BioSig Technologies Announces New Collaboration on Development of Artificial Intelligence Solutions in Healthcare

World News: . []

Westport, CT, Dec. 03, 2019 (GLOBE NEWSWIRE) --

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company entered into a technical collaboration with Reified Capital, a provider of advanced artificial intelligence-focused technical advisory services to the private sector. Reified was co-founded by Dr. Alexander D. Wissner-Gross and Timothy M. Sullivan, the founders of Gemedy.

The new collaboration with Cambridge, Massachusetts-based Reified will focus on developing a foundational artificial intelligence platform on the basis of integrated healthcare datasets, beginning with ECG and EEG data acquired by BioSig’s first product, PURE EP(tm) System - a novel real-time signal processing platform engineered to provide electrophysiologists with high fidelity cardiac signals. Electrophysiology focused technological solutions developed under the terms of this collaboration will be integrated into the PURE EP(tm) technology platform. Reified is led by Harvard- and MIT-trained computer scientist and physicist Dr. Wissner-Gross, an award-winning computer scientist, physicist, entrepreneur and author. Technical expertise that the Reified team is planning to bring to the project includes data analysis, algorithmic modeling and development.

“Integration of AI can open new avenues for improved diagnosis and more effective therapy delivery for bioelectronic medicine in particular and healthcare in general. We are thrilled to partner with Alex and his outstanding team, and look forward to working with them on developing world-class artificial intelligence and machine learning solutions, which, we believe, will benefit a worldwide physician audience,” commented Kenneth L Londoner, Chairman and CEO of BioSig Technologies, Inc.

“The application of modern AI and machine learning techniques to electrophysiology presents one of the most promising healthcare opportunities of our time,” said Dr. Wissner-Gross. “We look forward to our forthcoming collaboration with BioSig Technologies.” On November 21, 2019 the Company announced that it commenced in its first clinical trial for the PURE EP(tm) System.

Contact:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119




More news and information about BioSig Technologies, Inc.

Published By:

Globe Newswire: 12:52 GMT Tuesday 3rd December 2019

Published: .

Search for other references to "biosig" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us